Obsessive-Compulsive Disorder (OCD)

This report summarises what Blossom’s database shows about psychedelic and rapid-acting treatments for obsessive-compulsive disorder, and what it does not. The short version is a paradox: OCD is one of the oldest ideas in psychedelic psychiatry and one of the most mechanistically sensible, yet it has among the least developed evidence of any condition in the field. There is a reliable acute signal, a first small randomised win in 2026, and a reassuring safety record, set against tiny samples, mostly open-label data, unknown durability, and no approved treatment.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for OCD; the established, effective treatments are SSRI medication and exposure and response prevention therapy, and they should be the first port of call. OCD is highly treatable, and decisions about treatment, including any novel or rapid-acting option, belong with a qualified clinician. If you are struggling, please reach out to a health professional.

A word on scope and numbers. Blossom tracks dozens of papers and trials under this topic, and those counts appear on the page. The tag is broad: it includes mechanism and brain-imaging work, studies of related conditions such as body dysmorphic disorder, and trials only now recruiting. The genuinely OCD-clinical, results-bearing core is a small fraction of the headline, and it is honestly a small literature in absolute terms. Read the counts as breadth of interest, not depth of proof.

Why OCD is the field’s oldest and most logical idea

Most psychedelic indications are recent. OCD is not. The first prospective trial of psilocybin for OCD was published in 2006, years before the depression studies that defined the modern field, and informal reports of OCD relief during psychedelic experiences go back further still. There is also a strong mechanistic reason to expect an effect: OCD is the one major psychiatric condition already treated primarily with serotonergic drugs (SSRIs), so a serotonergic psychedelic acting on the 5-HT2A receptor is a natural extension rather than a leap. A 2024 review lays out this rationale and the proposed mechanisms in detail[1]Int J Neuropsychopharmacol, psychedelics-for-OCD review (2024), including the idea that psychedelics may loosen the rigid, repetitive thought patterns that characterise the disorder.

The landmark study, and a clue about mechanism

The foundational result is small but important. In a 2006 open-label study, nine patients with treatment-resistant OCD received up to four single doses of psilocybin across a range of strengths, and every participant showed a marked reduction in symptoms (between 23% and 100% on the Yale-Brown obsessive-compulsive scale) during at least one session, with only mild, transient side effects[2]J Clin Psychiatry, psilocybin OCD n=9 (2006). Two features are worth dwelling on. First, the effect was rapid, often emerging within hours, which is unusual for a condition that normally responds only slowly. Second, there was a significant effect of time but no significant effect of dose: higher doses did not reliably produce bigger improvements.

That absence of a dose-response is a genuine clue. In depression, the antidepressant effect tends to track the size of the dose and the intensity of the experience. If the anti-OCD effect does not, it raises the possibility that something other than the full psychedelic experience is doing the work, or that the relevant mechanism in OCD is different. It is exactly the kind of question a larger trial should be designed to answer, and exactly the kind that small studies cannot.

The 2026 trial: a first controlled win, read carefully

For almost twenty years the OCD evidence consisted of that 2006 study, case reports and surveys. In 2026, the original group published the first randomised trial: a double-blind phase compared low-dose and high-dose psilocybin against an active placebo (lorazepam), followed by an open-label phase of repeated high doses[3]J Psychopharmacol, repeated-dose psilocybin OCD RCT (2026). The blinded result was positive in direction: psilocybin, but not placebo, significantly reduced OCD scores, with the high dose separating most clearly the day after dosing. This is the first time a psychedelic has beaten a control condition for OCD, and the use of an active placebo (which mimics some drug effects) is a methodological strength.

The caution is equally important. Only five patients completed each arm of the blinded phase, which is very small. And the figures that make headlines, 73% responders and 40% in remission at eight weeks, easing to roughly 57% and 21% at six months[3]J Psychopharmacol, repeated-dose psilocybin OCD RCT (2026), come from the open-label extension in which everyone knew they were receiving repeated high doses of psilocybin. Open-label numbers in this field are inflated by expectancy, so they cannot be read as the trial’s controlled effect. The honest summary is a real but tiny controlled signal, wrapped in a larger set of uncontrolled results that look more impressive than the design can support.

Ketamine: fast, but it does not last

A separate line of work uses ketamine, which acts on glutamate rather than the classic-psychedelic pathway. A 2013 randomised crossover trial in 15 drug-free OCD patients found that half met response criteria one week after a single ketamine infusion, versus none after saline, with some reporting their obsessions lifting during the infusion itself[4]Neuropsychopharmacology, ketamine OCD crossover RCT (2013). For a disorder usually considered slow to treat, that immediacy was notable and helped spark interest in rapid-acting mechanisms.

But the effect is fragile. It generally fades within a week, and a 2024 double-blind, active-controlled crossover study in treatment-resistant OCD produced a more mixed result[5]J Psychopharmacol, ketamine treatment-resistant OCD crossover (2024). Research is now focused on whether repeated dosing, ketamine’s metabolites, or a better understanding of the underlying mechanism can turn a dramatic but transient effect into something durable. As it stands, ketamine in OCD is a fast effect without a reliable way to sustain it.

What about naturalistic use and other compounds?

Beyond the formal trials, a 2023 retrospective survey of people who used psychedelics outside the clinic reported improvements in OCD symptoms[6]Scientific Reports, retrospective OCD-and-psychedelics survey (2023). Findings like this are worth knowing but are weak evidence: they rely on self-report, are prone to recall and selection bias, and capture the people for whom it worked more readily than those for whom it did not. They motivate trials; they do not substitute for them. For MDMA, there is as yet no OCD efficacy data at all, only a single ongoing trial testing it as an adjunct to therapy.

Reading this honestly

So where does OCD sit? It is the field’s most tantalising near-miss: an old, mechanistically sound idea with a reproducible acute effect and a clean safety record, that has never been given the large, rigorous trial it needs. The 2026 randomised result is a genuine step, the first time psilocybin has beaten a control for OCD, but it is small, and its best numbers are open-label. The most careful recent review reaches the same verdict: promising, biologically plausible, and still limited to small studies with real methodological gaps[1]Int J Neuropsychopharmacol, psychedelics-for-OCD review (2024). For people living with OCD, the truthful message is that this is one of the more scientifically interesting frontiers in psychedelic medicine, and also one of the least settled: encouraging enough to take seriously, far too preliminary to rely on, and no substitute for the SSRIs and exposure therapy that remain the proven standard of care.